|
|
||||||||||||||
|
|
|||||||||||||||
LETTER |
Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Correspondence to:
Correspondence to:
Dr Diane M Janowicz
dmjanowi@iupui.edu
Keywords: cytomegalovirus; ventriculitis; immune reconstitution syndrome
| The first 150 words of the full text of this article appear below. |
Successful treatment of CMV ventriculitis immune reconstitution syndrome
In HIV infected patients, cytomegalovirus (CMV) disease of the central nervous system is usually seen when the CD4+ count is less than 100 cells/mm3. Recommended treatment includes intravenous ganciclovir, foscarnet, or both.1 Ventriculitis is an uncommon but severe manifestation of CMV disease. Mortality is extremely high despite timely initiation of treatment. Little is known about CMV ventriculoencephalitis in the highly active antiretroviral therapy (HAART) era.
Case report
A 38 year old woman with no significant past medical history was diagnosed with Pneumocystis jiroveci (Pneumocystis carinii) pneumonia as her AIDS defining illness in April 2002. On 15 July 2002, HAART was initiated with zidovudine, lamivudine, and efavirenz. Her CD4+ count was 42 cells/mm3 and her HIV-1 RNA level was 95 000 copies/ml. Serum CMV IgG was positive.
Ten days later, she was evaluated for headache of new onset. Computed tomography (CT) of her head was unremarkable. Cerebrospinal fluid analysis showed no white
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |